A Single Center, Open-label Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Allogeneic Dopaminergic Neural Precursor Cell(iDAP) Injection in the Treatment of Parkinson's Disease

Trial ID: NCT06583291

Interventional - Phase 1 - Not yet recruiting

The goal of this clinical trial is to evaluate the safety, tolerability and preliminary efficacy that iDAP has on Parkinson's disease (PD) patients.

Conditions

• Parkinson Disease

Interventions

• Allogeneic dopaminergic neural precursor cell(iDAP)

Eligibility

Inclusion criteria

• - Ages between 45 and 75 years;
• Diagnosed to be Parkinson's disease patients according to MDS Parkinson's disease diagnostic criteria;
• Disease history 4-20 years;
• Hoehn and Yahr Stage 2-4;
• Stable dose of dopamine for more than 3 months;
• Improvement of MDS-UPDRS part III;

Exclusion criteria

• - Patients who have previously undergone brain surgery;
• Past use of stem cell therapy or participation in stem cell clinical research;
• Cognitive impairment;
• History of mental disorders;
• Patients with other serious systemic diseases;
• Past or current metastatic malignant tumors.

Sponsor

Anhui Provincial Hospital

Last updated: 2025-05-26 · Source: Clinicaltrials.gov

Search more clinical trials on myTomorrows